Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lorpucitinib
JNJ-64251330 · 1 trial · 1 indication
Percentage change from baseline in colorectal polyp burden for all polyps (the sum of the polyp diameters) at Week 24 will be reported.
Percentage change from baseline in colorectal polyp burden (sum of the polyp diameters) for polyps greater than or equal to (\>=) 2 millimeters (mm) at Week 24 will be reported.
| Arm | Type | Description |
|---|---|---|
| JNJ-64251330 | EXPERIMENTAL | Participants will receive oral dose of JNJ-64251330 twice daily for 24 Weeks. |
| Name | Type | Description |
|---|---|---|
| JNJ-64251330 | DRUG | JNJ-64251330 tablets will be administered orally. |
Inclusion Criteria: * Genetic diagnosis of classical familial adenomatous polyposis (FAP) (adenomatous polyposis coli \[APC\] germline mutation or obligate carrier) with disease involvement of the colorectum * At least 6 polyps greater than or equal to (\>=) 2 millimeters (mm) in diameter in the re...
JNJ-64251330 is an investigational small molecule developed by Johnson & Johnson for Adenomatous Polyposis Coli, a gastrointestinal condition. It has completed a Phase 1 clinical trial and is not yet approved for any indication.
JNJ-64251330 is being studied for the treatment of Adenomatous Polyposis Coli, a gastrointestinal condition characterized by multiple adenomas in the colon and rectum. It is investigational and has not been approved for any use.
JNJ-64251330 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker symbol JNJ. The company is responsible for the clinical development of this small molecule for Adenomatous Polyposis Coli.
JNJ-64251330 has completed a Phase 1 clinical trial. It remains an investigational drug and has not received FDA approval. No later-phase trials are currently active.
JNJ-64251330 was evaluated in a Phase 1 trial, NCT05014360, titled A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis. The trial enrolled 42 participants across the United States, France, Germany, Netherlands, Puerto Rico, South Korea, and Spain, and is now completed.